Michael Milken, chairman of the Milken Institute and of Faster Cures, and the man Fortune magazine said “changed medicine,” will be the keynote speaker for The Bonnie J. Addario Lung Cancer Foundation’s Summit on Lung Cancer, which features the world’s leading researchers, November 9 and 10, 2007 at the University of California San Francisco at the Mission Bay Conference Center. (Day One: 7:30am-4:00pm, Day Two: 8:30am – 12pm) Michael Milken will be speaking on Friday morning from 8:15-9:45am. The Summit is by invitation only. Credentials and 48-hour notice for press are required.

Lung cancer patients with emphasis on the past, often simply typing Chinese medicine or Western medicine type, and then simply carried out the treatment of traditional Chinese medicine or Western medicine, traditional Chinese and western medicine with the clinical treatment play an increasingly important role in lung cancer sub-type also appeared in type of traditional Chinese and western medicine.

A Centennial company called Cell>Point is developing a new way to diagnose and treat cancer. Some doctors are already calling the techniques exciting and revolutionary, and the developments could offer new hope in the fight against cancer.

Cell>Point is developing two different products: a diagnostic tool that will help doctors diagnose and examine a cancer tumor, and a therapeutic tool that will actually treat the cancer.

Researchers at the University of Texas M.D. Anderson Cancer Center first discovered the technique that attaches chemicals to Glucosamine, a molecule of sugar.

Lung cancer is the leading cause of cancer death in the United States for both men and women and continues to have a five-year survival rate of less than 10%. Currently, complete surgical resection remains the best hope for cure. However, not all patients with lung cancer are candidates for surgical resection. This article describes the process used in selecting patients who are eligible for lung cancer resection. After determining that lung cancer is present, it is important to assess the resectability of the tumor as well as the suitability of the patient for an operation evaluating the histological type of cancer, the degree of invasion, and the patient’s other medical conditions.

Surgery alone offers a reasonable overall level of survival for patients with stage 1 small cell lung cancer, a new study suggests.

Traditional treatment regimens for limited stage SCLS include chemotherapy and radiotherapy.

In this study, researchers analyzed U.S. National Cancer Institute data on the outcomes of 247 patients with stage 1 SCLC who had surgery to remove a lung (lobectomy).

The three- and five-year survival rates for patients who had surgery alone were 58.1 percent and 50.3 percent, respectively. The three- and five-year survival rates for patients who had surgery followed by radiotherapy (RT) were 64.9 percent and 57.1 percent, respectively.

Cancers can be genetically tested to determine how dangerous they are, whether patients have been cured, and to possibly spare some patients from unnecessary chemotherapy, according to research from the Johns Hopkins Kimmel Cancer Center.

The research, released Thursday at the annual meeting of the American Association for the Advancement of Science, shows how personalizing treatment can help fight cancer, said Luis A. Diaz, a researcher at the Baltimore center.

Genetics hasn’t delivered the fabled “magic bullet” to eradicate cancer, Diaz said. However, the discovery that the genetic abnormalities found in cancers have individual fingerprints is an unexpected benefit.

It will probably take about two years to move the test out of the research stage so it’s widely available to doctors, Diaz said.

Lung cancer is the second-most commonly diagnosed cancer in both men and women, and it is still the most common cause of cancer death, according to the American Lung Association.

Duke researchers said they believe they’ve found one reason why some lung cancer patients fight the disease better than others.

In the past, doctors have diagnosed a disease, and often, all doctors treated that particular disease in the same way with the same drugs. Now, DNA testing is allowing doctors to treat each individual patient and not just the disease.

This more specific treatment will give patients targeted therapies and better results.

Personalized medicine is already benefiting patients today, especially those suffering from certain types of cancer.

University of Colorado Hospital patient Andy Hill says that less than one year ago, he “had chest pains, considerable fatigue – hard to get out of bed in the mornings.”

Hill was fighting stage 3 lung cancer with metastasis. He was exhausted and could hardly climb the stairs in his house back in Seattle.

Hill says his cancer diagnosis caught everyone by surprise.

Surgery alone offers a reasonable overall level of survival for patients with stage 1 small cell lung cancer, a new study suggests.

Traditional treatment regimens for limited stage SCLS include chemotherapy and radiotherapy.

In this study, researchers analyzed U.S. National Cancer Institute data on the outcomes of 247 patients with stage 1 SCLC who had surgery to remove a lung (lobectomy).

According to a recent study, the utilization of surgery alone in selected patients with stage one small cell lung cancer (SCLC) produces an excellent overall survival rate. Traditionally, treatment regiments include the use of chemotherapy and radiotherapy.

U.S. researchers analyzed the medical data of nearly 250 patients with stage 1 SCLC who had surgery to remove a lung. They found that the three- and five-year survival rates for the patient group who underwent lobectomies without radiation therapy were 58.1 percent and 50.3 percent, respectively.